<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82198">
  <stage>Registered</stage>
  <submitdate>7/08/2007</submitdate>
  <approvaldate>17/08/2007</approvaldate>
  <actrnumber>ACTRN12607000418471</actrnumber>
  <trial_identification>
    <studytitle>A pilot phase II open-label study of oglufanide disodium in patients with chronic hepatitis C</studytitle>
    <scientifictitle>In patients with chronic hepatitis C, does treatment with oglufanide disodium reduce viral load from baseline value?</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>IM07-02</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Chronic hepatitis C</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Intranasal oglufanide disodium 0.05 mg twice daily for 21 days</interventions>
    <comparator>None</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Perecentage with greater than 2-log reduction in viral load.</outcome>
      <timepoint>4 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>1. Duration of response</outcome>
      <timepoint>Based on measurement of viral load at 4-weekly intervals</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>2. % with sustained viral response</outcome>
      <timepoint>At 12 and 24 weeks after the start of treatment.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>3. % of patients with greater than 2-fold reduction in serum transaminases</outcome>
      <timepoint>at any time after the start of treatment</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Serological evidence of infection with hepatitis C virus (HCV), including anti-HCV antibodies and viral load at least 100 time sgreate tha the lower limit of detection.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Co-infection with hepatitis B or human immunodeficiency virus (HIV)
2. Severe liver disease, or liver disease due to other disorders
3. Renal, hepatic or bone marrow dysfunction
4. Active or suspected cancer or histor of malignancy with high risk of recurrence
5. Organ transplant
6. Substance abuse
7. Women of childbearing potential</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>8/08/2007</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>17</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up complete</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Implicit Bioscience Pty Ltd</primarysponsorname>
    <primarysponsoraddress>Level 1, 80 Jephson Street, Toowong, QLD 4066</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Implicit Bioscience Pty Ltd</fundingname>
      <fundingaddress>Level 1, 80 Jephson Street, Toowong, QLD 4066</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>None</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary purpose of the study is to assess the efficacy of the drug in reducing viral load in patients with chronic HCV infection</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Monash Medical Centre</ethicname>
      <ethicaddress>Clayton VIC</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Rachel Fahy</name>
      <address>Implcit Bioscience Pty Ltd
Level 1
80 Jephson Street
Toowong QLD 4066</address>
      <phone>+61 7 3721 1242</phone>
      <fax>07 3719 5499</fax>
      <email>rachel.fahy@implicitbioscience.com</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Rachel Fahy</name>
      <address>Implicit Bioscience Pty Ltd
Level 1
80 Jephson Street
Toowong QLD 4066</address>
      <phone>+61 7 3721 1242</phone>
      <fax>07 3719 5499</fax>
      <email>rachel.fahy@implicitbioscience.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Rachel Fahy</name>
      <address />
      <phone>+61 7 3721 1242</phone>
      <fax />
      <email>rachel.fahy@implicitbioscience.com</email>
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>